TBUFF News Alert Tribute Pharmaceuticals Canada Inc. (TBUFF)

New Post Public Reply Private Reply Replies (0) Message Board

Dec 26, 2014 at 12:12 AM

Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.4600 $TBUFF

Tribute Pharma Q3 Update: Q4 Slated For Increase In Revenues
Anita Dushyanth - at Seeking Alpha - Thu Nov 13, 12:51PM CST

Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:29AM CST

Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.560 (unch), NVS: 93.91 (+0.66)

Tribute Pharmaceuticals Canada EPS of C$0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:52AM CST

Tribute Pharmaceuticals to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday, November 10, 2014
ACCESSWIRE - Fri Nov 07, 3:06PM CST
MILTON, ON / ACCESSWIRE / November 7, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TRX.V) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Monday, November 10, 2014 at 11:00 AM Eastern Time.

Tribute Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 1:47PM CST

CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 10:49AM CST
This release corrects and replaces the press release sent on November 3 at 10:26 AM ET for Tribute Pharmaceuticals Canada Inc. In the first paragraph, "second quarter ending September 30, 2014" has been changed to "third quarter ending September 30, 2014". The corrected version follows.
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
Marketwired - Mon Nov 03, 9:26AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, November 10, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending September 30, 2014.
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe
Marketwired - Thu Oct 30, 7:41AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"

, today announced that it has received a patent approval from the European Patent Office ("EPO"

for intellectual property central to one of the Company's lead products, Uracyst(R)/Uropol(R) (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan ("GAG"

deficient forms of cystitis or GAG-deficiency, such as, accompanying chronic urinary tract infection, radiation- induced cystitis, chemical-induced cystitis or hemorrhagic cystitis. The European patent coverage extends to drug compositions comprising a unit dose of chondroitin sulfate in an amount of at least 400 mgs and an aqueous vehicle. This patent will run until February 18, 2024.
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R)
Marketwire - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"

, is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products"

from Novartis AG ("Novartis"

for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million.
TRX.VN: 0.560 (unch), NVS: 93.91 (+0.66)

Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to FiorinalÂ®, FiorinalÂ® C, ViskenÂ® and ViskazideÂ®
Marketwire Canada - Thu Oct 02, 7:29AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"

, is pleased to announce that it has acquired the Canadian rights to Fiorinal(R), Fiorinal(R) C, Visken(R) and Viskazide(R) (the "Products"

from Novartis AG ("Novartis"

for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million.
TRX.VN: 0.560 (unch), NVS: 93.91 (+0.66)

Tribute Pharmaceuticals Receives 4th Uracyst(R) Patent in United States
Marketwire - Thu Sep 25, 8:20AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"

, today announced that it has received an additional patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property that is central to one of the Company's lead products, Uracyst(R) (a sterile sodium chondroitin sulfate solution, 2%, which is used in the treatment of interstitial cystitis / bladder pain syndrome ("IC/BPS"

).
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results
Marketwire - Mon Aug 11, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and U.S., today announced financial results for its quarter ending June 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.560 (unch)

Tribute Pharmaceuticals to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Monday, August 11, 2014
ACCESSWIRE - Fri Aug 08, 3:26PM CDT
MILTON, ONTARIO / ACCESSWIRE / August 8, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Monday, August 11, 2014 at 11:00 AM Eastern Time.
TRX.VN: 0.560 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quorum Joins LIVE Coalition to Revolutionize Estate Planning

Shaking Up Estate Planning: Quorum Joins LIVE Coalition Here's a fresh shake-up in the world of estate planning. Quorum Federal Credit Union has thrown its hat into the ring as the latest member of the LIVE Coalition, a band of financial, legal, and tech wizards putting estate plans on a modern track. This marks them as the 70th player to dive into this alliance, pushing...

Fiber Giants Unite to Boost Connectivity in Montana

Montana's Broadband Transformation Takes a Leap Folks in Northwest Montana, take note. Vero Fiber and MontanaSky have tied the knot, officially sealing a merger that doesn't just unite two reputable broadband providers but promises to shake up the internet game across the region. Just ask anyone who's tried to stream a movie during peak hours in Flathead Valley. A...

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Nukleus Launches Unified Platform for Athletes' Business

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

Li-Fire Expands Fire Safety Amid Rising Battery Risks

A Crunchy Look at New Fire Safety Moves Well, folks, here's a twist we didn't see coming but sure makes sense in today's electrifying business landscape. Li-Fire, the big brains behind lithium battery fire suppression, is spreading its wings nationwide, or at least its wholesale and distribution programs are. And right ahead of National Fire Safety Week no less—talk...

Sports Research Joins Costco: Creatine Mix Available

Breaking Into the Big League: Sports Research Hits Costco When a company's product finds its way onto Costco's shelves, you know they're not just playing in the minor leagues anymore. This October, Sports Research® made a bold move into the retail giant's sports nutrition section with their new Creatine + Electrolytes powder. It's not their first rodeo when it comes to...

Comparent Unveils Key Insights with Top 100 List

The Ebb and Flow of Vacation Rental Giants Ever noticed how some industries just sneak up and suddenly transform landscapes? Vacation rental management is one of those sneaky offenders. At the forefront of keeping tabs on this bustling sector, Comparent just dropped a meaty second annual roster—the Comparent 100—showcasing the biggest players flexing their muscles in...

Mitsubishi's Q3 Sales: SUVs Up, Mirage Out

You ever notice how the market treats innovation and tradition like they’re these ever-spinning plates in a circus act? Take Mitsubishi Motors North America (MMNA). Their third-quarter report's got me both nodding in approval and scratching my head. Sure, they sold 18,543 vehicles—down 5.6% from the previous year. But don’t write 'em off just yet. The slumping...

Cannatrol and Veterans Nonprofit Unite for Healing

Veterans Find a New Ally in Cannabis Tech When two distinct worlds collide for a cause, it can create waves of change much bigger than simple collaboration. That's exactly what's happening with Cannatrol and Operation Green Healing, a partnership that could redefine support for our veterans. Cannatrol, renowned for its groundbreaking post-harvest cannabis technology, has...